| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 123 | 122 | 114 | 485 | 131 | 129 | 171 | 144 | 134 | 184 | 144 | 173 | 136 | 234 | 158 | 1,821 | 151 | 143 | 157 | 163 | 163 | 149 | 159 | 150 | 122 | 155 | 170 | 169 |
| Expenses | 116 | 179 | 87 | 258 | 104 | 149 | 132 | 150 | 111 | 144 | 127 | 167 | 134 | 226 | 144 | 171 | 191 | 109 | 124 | 135 | 140 | 147 | 151 | 143 | 130 | 140 | 156 | 159 |
| EBITDA | 7 | -57 | 27 | 228 | 27 | -20 | 39 | -6 | 23 | 40 | 17 | 6 | 2 | 8 | 14 | 1,650 | -40 | 34 | 33 | 29 | 24 | 2 | 8 | 8 | -8 | 14 | 14 | 9 |
| Operating Profit % | -17 % | -48 % | 21 % | -110 % | 17 % | -19 % | 21 % | -19 % | 16 % | 21 % | 11 % | 1 % | -1 % | 3 % | 8 % | -21 % | -72 % | -4 % | -8 % | -4 % | -8 % | -2 % | -0 % | -4 % | -12 % | 5 % | 5 % | -20 % |
| Depreciation | 14 | 14 | 52 | 13 | 11 | 11 | 11 | 10 | 11 | 11 | 11 | 12 | 11 | 11 | 11 | 11 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 8 |
| Interest | 25 | 29 | -14 | 26 | 41 | 42 | 47 | 45 | 45 | 48 | 46 | 47 | 48 | 50 | 52 | 31 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | -33 | -99 | -11 | 189 | -25 | -73 | -19 | -61 | -34 | -19 | -40 | -53 | -57 | -53 | -49 | 1,608 | -51 | 23 | 22 | 18 | 13 | -8 | -2 | -2 | -17 | 5 | 4 | 0 |
| Tax | 3 | -2 | 5 | 3 | 3 | 2 | 2 | 9 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 371 | 5 | 8 | 3 | 31 | 2 | 1 | 1 | -0 | -1 | 0 | -0 | 2 |
| Net Profit | -35 | -97 | -16 | 186 | -28 | -75 | -21 | -70 | -34 | -19 | -40 | -54 | -57 | -53 | -49 | 1,238 | -56 | 16 | 19 | -13 | 11 | -8 | -2 | -2 | -16 | 5 | 4 | -2 |
| EPS in ₹ | -5.75 | -15.83 | -2.60 | 30.35 | -4.62 | -12.25 | -3.48 | -11.38 | -5.58 | -3.16 | -6.54 | -8.84 | -9.36 | -8.65 | -8.03 | 202.03 | -9.17 | 2.56 | 3.16 | -2.03 | 1.79 | -1.35 | -0.37 | -0.23 | -2.59 | 0.77 | 0.74 | -0.31 |
Panacea Biotec
Panacea Biotec
412.30
-12.35
(-2.91%)
There are new updates from the company1 day ago
View
Market Cap
2,525.37 Cr
EPS
-1.37
PE Ratio
-
Dividend Yield
0.00 %
Industry
Healthcare52 Week High
581.90
52 Week Low
131.76
PB Ratio
3.12
Debt to Equity
0.02
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Company News
View All News
Panacea Biotec Limited received approval from BSE and NSE to reclassify Mrs. Sunanda Jain, Mr. Sumit Jain, and Ms. Radhika Jain from the Promoters and Promoters' Group category to the Public category of shareholders. The company had applied for this reclassification on October 16, 2024, and received approval on July 29, 2025. Despite this reclassification, there will be no change in the aggregate shareholding of Promoters and Promoters' Group as none of the outgoing members hold any shares in the company. The promoter holding remains at 4,43,94,190 shares (72.48%) and public holding stays at 1,68,56,556 shares (27.52%) both pre and post-reclassification.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,733.80 | #1 4,15,996.70 | 35.83 | #1 54,729.00 | 12.06 | #1 10,980 | -18.99 | 64.93 | |
6,650.00 | 1,76,536.61 | 80.94 | 9,712.00 | 0.89 | 2,191 | 23.05 | 46.65 | |
3,730.60 | 1,26,260.46 | 63.15 | 11,539.40 | 6.99 | 1,911 | 19.91 | 74.11 | |
1,559.40 | 1,25,953.96 | 23.58 | 28,409.50 | 7.12 | 5,291 | 9.88 | 65.36 | |
1,292.10 | 1,07,834.93 | #1 19.10 | 33,741.20 | 16.73 | 5,725 | 1.26 | 55.19 | |
2,575.50 | 1,06,298.29 | 60.68 | 12,744.20 | 19.57 | 2,007 | -10.91 | 55.92 | |
995.15 | 1,00,135.38 | 21.54 | 23,511.00 | 13.82 | 4,615 | -0.19 | 61.25 | |
1,984.60 | 90,635.78 | 27.91 | 22,909.50 | #1 19.94 | 3,306 | #1 112.49 | 58.19 | |
35,195.00 | 74,786.92 | 52.17 | 6,684.70 | 10.80 | 1,414 | 27.83 | 60.78 | |
1,158.00 | 67,256.83 | 19.47 | 31,378.10 | 17.55 | 3,366 | -0.50 | 55.87 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
14.35 %
Net Income Growth
-95.55 %
Cash Flow Change
99.98 %
ROE
-95.52 %
ROCE
-70.49 %
EBITDA Margin (Avg.)
-110.83 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 1,931 | 1,854 | 1,800 | 1,608 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,241 | 1,290 |
| Fixed Assets | 1,144 | 1,071 | 1,001 | 949 | 806 | 657 | 609 | 622 | 600 | 582 | 695 |
| Current Assets | 526 | 549 | 533 | 560 | 508 | 683 | 511 | 951 | 562 | 485 | 545 |
| Capital Work in Progress | 156 | 161 | 30 | 40 | 23 | 24 | 34 | 17 | 42 | 102 | 94 |
| Investments | 5 | 4 | 7 | 7 | 5 | 6 | 0 | 5 | 14 | 40 | 214 |
| Other Assets | 626 | 619 | 761 | 611 | 542 | 703 | 534 | 1,115 | 615 | 517 | 0 |
| Total Liabilities | 1,931 | 1,854 | 1,800 | 1,608 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,241 | 1,290 |
| Current Liabilities | 706 | 475 | 588 | 691 | 938 | 452 | 449 | 776 | 330 | 309 | 367 |
| Non Current Liabilities | 750 | 930 | 846 | 611 | 90 | 743 | 960 | 109 | 101 | 94 | 92 |
| Total Equity | 475 | 450 | 366 | 306 | 347 | 196 | -232 | 874 | 840 | 838 | 835 |
| Reserve & Surplus | 449 | 426 | 340 | 293 | 335 | 139 | -257 | 849 | 816 | 814 | 829 |
| Share Capital | 22 | 22 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -1 | -10 | -2 | 9 | -2 | 26 | 12 | -2 | -11 | 7 |
| Investing Activities | -37 | 17 | -26 | 55 | -6 | -35 | -48 | 1,283 | 430 | 10 |
| Operating Activities | 37 | 91 | 131 | 118 | 105 | -31 | 107 | -108 | -423 | -0 |
| Financing Activities | -1 | -117 | -107 | -164 | -101 | 91 | -47 | -1,176 | -18 | -3 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 73.59 % | 73.59 % | 73.59 % | 73.59 % | 73.59 % | 73.59 % | 73.59 % | 73.59 % | 73.59 % | 73.59 % | 73.59 % | 73.59 % | 73.59 % | 73.46 % | 72.87 % | 72.49 % | 72.48 % | 72.48 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.27 % | 0.27 % | 0.37 % | 0.38 % | 1.16 % | 0.78 % |
| DIIs | 1.27 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.29 % | 0.43 % | 0.43 % | 0.54 % | 0.00 % | 0.00 % | 0.84 % | 1.07 % | 1.16 % | 1.17 % | 1.49 % | 1.52 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 17.34 % | 15.21 % | 15.57 % | 15.99 % | 15.14 % | 15.60 % | 15.79 % | 15.97 % | 15.82 % | 16.15 % | 19.20 % | 19.63 % | 19.90 % | 20.42 % | 18.11 % | 18.98 % | 18.45 % | 18.17 % |
| Others | 7.80 % | 11.20 % | 10.84 % | 10.42 % | 11.27 % | 10.81 % | 10.33 % | 10.02 % | 10.16 % | 9.73 % | 7.21 % | 6.78 % | 5.40 % | 4.79 % | 7.49 % | 6.99 % | 6.41 % | 7.05 % |
| No of Share Holders | 27,228 | 54,313 | 52,816 | 52,465 | 49,563 | 49,896 | 49,078 | 50,533 | 48,634 | 47,815 | 48,878 | 47,091 | 46,242 | 45,513 | 39,982 | 35,446 | 33,593 | 34,256 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 30 May 2025 |  Quarterly Result Announcement | NA | 30 May 2025 | 528.95 | 520.90 |
| 14 Feb 2025 | Quarterly Result Announcement | NA | 14 Feb 2025 | 324.90 | 343.15 |
| 13 Nov 2024 | Quarterly Result Announcement | NA | 13 Nov 2024 | 303.15 | 340.50 |
| 12 Nov 2024 | Quarterly Result Announcement | NA | 12 Nov 2024 | 349.80 | 349.80 |
| 27 Sept 2024 |  Annual General Meeting | NA | 27 Sept 2024 | 332.95 | 273.05 |
Announcements
Intimation Under Regulation 30 And Regulation 31A(8) Of The Securities & Exchange Board Of India (Listing Obligations & Disclosure Requirements) Regulations 2015 - Approval For Reclassification Of Mrs. Sunanda Jain Mr. Sumit Jain And Ms. Radhika Jain Fro
1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Newspaper PublicationJul 19, 2025
Jul 19, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 11, 2025
Jul 11, 2025Intimation Of Settlement Of Disputes With Apotex Inc. Canada
Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 09, 2025
Jul 09, 2025Details Of Shares Dematerialised During June 2025 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations 2018Jul 07, 2025
Jul 07, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2025
Jul 07, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Details Of Shares Dematerialised During May 2025 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations 2018Jun 06, 2025
Jun 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 31, 2025
May 31, 2025Intimation Regarding Appointment Of Secretarial AuditorMay 30, 2025
May 30, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
May 30, 2025Standalone And Consolidated Audited Financial Results Along With Auditors Report For The Quarter And Financial Year Ended March 31 2025May 30, 2025
May 30, 2025Board Meeting Outcome for 1. Standalone And Consolidated Audited Financial Results Along With Auditors Report For The Quarter And Financial Year Ended March 31 2025
2. Passing Over Of Dividend For The Financial Year 2024-25
3. Appointment Of SecretarMay 30, 2025
May 30, 2025Board Meeting Intimation for For Approval Of The Audited Financial Results For The Quarter And Financial Year Ended March 31 2025 And Passing Over Of Dividend On Equity As Well As Preference Shares For The Said Financial Year.May 24, 2025
May 24, 2025Nation-Wide Study Undertaken By Panacea Biotec Pharma Ltd. (Material WOS) Confirms Chilrun Full Accelerates Growth And Development In ChildrenMay 19, 2025
May 19, 2025Details Of Shares Dematerialized During April 2025 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations 2018May 06, 2025
May 06, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 29, 2025
Apr 29, 2025Receipt Of An Additional Award From UNICEF For Supply Of Bivalent Oral Polio Vaccine (Bopv) Worth ~US$ 5.20 Million In Q3 CY2025Apr 23, 2025
Apr 23, 2025Details Of Shares Dematerialized During March 2025Apr 07, 2025
Apr 07, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 03, 2025
Apr 03, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 01, 2025
Apr 01, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateApr 01, 2025
Apr 01, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 31, 2025
Mar 31, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMar 31, 2025
Mar 31, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMar 30, 2025
Mar 30, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025Clarification On Movement In PriceMar 12, 2025
Mar 12, 2025Clarification sought from Panacea Biotec LtdMar 11, 2025
Mar 11, 2025Demat Report For The Month Of February 2025Mar 04, 2025
Mar 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 28, 2025
Feb 28, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 27, 2025
Feb 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 15, 2025
Feb 15, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 15, 2025
Feb 15, 2025Integrated Filing (Financial)Feb 14, 2025
Feb 14, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 14, 2025
Feb 14, 2025Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Nine Months Ended December 31 2024Feb 14, 2025
Feb 14, 2025Board Meeting Outcome for 1. Unaudited Financial Results For The Quarter And Nine Months Ended 31.12.2024
2. Appointment / Re-Appointment Of Directors
3. Change In Senior Management Personnel
4. ReFeb 14, 2025
Feb 14, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 13, 2025
Feb 13, 2025Demat Report For The Month Of January 2025Feb 07, 2025
Feb 07, 2025Board Meeting Intimation for Approval Of Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter And Nine Months Ended December 31 2024Jan 31, 2025
Jan 31, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI LODR Regulations)Jan 23, 2025
Jan 23, 2025Details Of Shares Dematerialized During December 2024Jan 07, 2025
Jan 07, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2025
Jan 07, 2025Intimation Regarding Launch Of Baby Diapers And Wipes By CompanyS Wholly-Owned Subsidiary Panacea Biotec Pharma LimitedJan 03, 2025
Jan 03, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJan 01, 2025
Jan 01, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportDec 28, 2024
Dec 28, 2024Intimation Of Further Investment In Panacea Biotec Inc. Made By The CompanyS Material Subsidiary Panacea Biotec Pharma LimitedDec 28, 2024
Dec 28, 2024Announcement under Regulation 30 (LODR)-Change in ManagementDec 09, 2024
Dec 09, 2024Details Of Shares Dematerialized During November 2024Dec 06, 2024
Dec 06, 2024Technical Indicators
RSI(14)
Neutral 44.63
ATR(14)
Less Volatile 19.53
STOCH(9,6)
Neutral 38.71
STOCH RSI(14)
Neutral 43.66
MACD(12,26)
Bullish 1.02
ADX(14)
Weak Trend 17.43
UO(9)
Bearish 40.95
ROC(12)
Downtrend And Accelerating -0.93
WillR(14)
Neutral -74.46
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
